Mechanism-based concepts of size and maturity in pharmacokinetics

被引:872
|
作者
Anderson, B. J. [1 ]
Holford, N. H. G. [2 ]
机构
[1] Univ Auckland, Sch Med, Dept Anaesthesiol, Auckland 1, New Zealand
[2] Univ Auckland, Sch Med, Dept Pharmacol & Clin Pharmacol, Auckland 1, New Zealand
关键词
allometry; weight; growth; maturation; postmenstrual age;
D O I
10.1146/annurev.pharmtox.48.113006.094708
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Growth and development can be investigated using readily observable demographic factors such as weight and age. Size is the primary covariate and can be referenced to a 70-kg person with allometry using a coefficient of 0.75 for clearance and 1 for volume. The use of these coefficients is supported by fractal geometric concepts and observations from diverse areas in biology. Fat free mass (FFM) might be expected to do better than total body weight when there are wide variations in fat affecting body composition. Clearance pathways develop in the fetus before birth. The use of postnatal age as a descriptor of maturation is unsatisfactory because birth may occur prematurely; therefore postmenstrual age is a superior predictor of elimination function. A sigmoid E-max model (Hill equation) describes gradual maturation of clearance in early life leading to a mature adult clearance achieved at a later age.
引用
收藏
页码:303 / 332
页数:30
相关论文
共 50 条
  • [21] MECHANISM-BASED PREDICTIONS OF INTERACTIONS
    OESCH, F
    OESCHBARTLOMOWICZ, B
    ARENS, J
    FAHNDRICH, F
    VOGEL, E
    FRIEDBERG, T
    GLATT, H
    ENVIRONMENTAL HEALTH PERSPECTIVES, 1994, 102 : 5 - 9
  • [22] Context in Mechanism-Based Explanation
    Pozzoni, Gianluca
    Kaidesoja, Tuukka
    PHILOSOPHY OF THE SOCIAL SCIENCES, 2021, 51 (06) : 523 - 554
  • [23] MECHANISM-BASED INHIBITORS OF ELASTASE
    GROUTAS, WC
    BADGER, RC
    OCAIN, TD
    FELKER, D
    FRANKSON, J
    THEODORAKIS, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1980, 95 (04) : 1890 - 1894
  • [24] Mechanism-based therapies for pain
    Block, BM
    Hurley, RW
    Raja, SN
    DRUG NEWS & PERSPECTIVES, 2004, 17 (03) : 172 - 186
  • [25] MECHANISM-BASED ENZYME INACTIVATORS
    WALSH, C
    FEDERATION PROCEEDINGS, 1980, 39 (06) : 1667 - 1667
  • [26] MECHANISM-BASED SIRTUIN INHIBITION
    Zheng, Weiping
    ANTICANCER RESEARCH, 2014, 34 (10) : 6254 - 6255
  • [27] Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA
    Yang, Jiansong
    Jamei, Masoud
    Heydari, Amir
    Yeo, Karen R.
    de la Torre, Rafael
    Farre, Magi
    Tucker, Geoffrey T.
    Rostami-Hodjegan, Amin
    JOURNAL OF PSYCHOPHARMACOLOGY, 2006, 20 (06) : 842 - 849
  • [28] Mechanism-based biomarker discovery
    Antoranz, Asier
    Sakellaropoulos, Theodore
    Saez-Rodriguez, Julio
    Alexopoulos, Leonidas G.
    DRUG DISCOVERY TODAY, 2017, 22 (08) : 1209 - 1215
  • [29] Assessment of translational risk in drug research: Role of biomarker classification and mechanism-based PKPD concepts
    Visser, Sandra A. G.
    Bueters, Tjerk J. H.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 109 : S72 - S77
  • [30] Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model
    Fransson, Martin N.
    Green, Henrik
    Litton, Jan-Eric
    Friberg, Lena E.
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (02) : 247 - 255